Use of granulocyte colony-stimulating factor (G-CSF) and outcome in patients with non-chemotherapy agranulocytosis

L. Ibáñez, M. Sabaté, E. Ballarín, R. Puig, X. Vidal, J. R. Laporte

Research output: Contribution to journalArticleResearchpeer-review

13 Citations (Scopus)

Abstract

Purpose: The use of granulocyte colony-stimulating factor (G-CSF) in the treatment of non-chemotherapy drug- induced agranulocytosis is controversial. We aimed at assessing the effect of G-CSF on the duration of agranulocytosis. Methods: To assess the effect of G-CSF on the duration of agranulocytosis, a Cox proportional hazard model with an estimated propensity score covariate adjusting for several prognostic factors was used. Results: One hundred and forty-five episodes of agranulocytosis were prospectively collected from January 1994 to December 2000 in Barcelona (Spain). No differences were found in the case-fatality rate between treated (9 of 101, 8.9%) and not treated (5 of 44, 11.4%) patients. The median time to reach a neutrophil count ≥1.0 × 109/L was 5 days (95%CI 5-6) in patients treated with G-CSF compared to 7 days (95%CI 6-8) in those not treated, with a hazard ratio of 1.58 (95% CI 1.1-2.3). Conclusions: G-CSF shortens time to recovery in patients with agranulocytosis. However, as an effect on case-fatality has not been recorded, and data on cost-effectiveness are lacking, it would be wise to restrict its use to high-risk patients. Copyright © 2008 John Wiley & Sons, Ltd.
Original languageEnglish
Pages (from-to)224-228
JournalPharmacoepidemiology and Drug Safety
Volume17
DOIs
Publication statusPublished - 1 Mar 2008

Keywords

  • Drug-induced agranulocytosis
  • Filgrastim
  • Granulocyte colony-stimulating factor
  • Neutropenia

Fingerprint

Dive into the research topics of 'Use of granulocyte colony-stimulating factor (G-CSF) and outcome in patients with non-chemotherapy agranulocytosis'. Together they form a unique fingerprint.

Cite this